SATO Seiya 佐藤誠也

Researcher Number	30621007
Other IDs
Affiliation (Current)	2021: 島根大学, 学術研究院医学・看護学系, 助教
Affiliation (based on the past Project Information) *help	2015 – 2019: 岩手医科大学, 医学部, 助教 2012 – 2014: 鳥取大学, 医学部附属病院, 助教
Review Section/Research Field	Except Principal Investigator Obstetrics and gynecology / Basic Section 56040:Obstetrics and gynecology-related
Keywords	Except Principal Investigator 卵巣癌 / 明細胞癌 / 卵巣明細胞腺癌 / FGFR2 / 明細胞腺癌 / PI3K / PIK3CA / PI3K阻害剤 / mTOR阻害剤 / 卵巣明細胞癌 … More

卵巣明細胞癌に対するNEFHを標的とした新規治療法の開発Ongoing
- Principal Investigator
  
  板持広明
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56040:Obstetrics and gynecology-related
- Research Institution
  Iwate Medical University
The KANK1 pathway may be a novel therapeutic target for ovarian clear cell carcinoma
- Principal Investigator
  
  ITAMOCHI Hiroaki
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Obstetrics and gynecology
- Research Institution
  Iwate Medical University
Development of combination therapy using PI3K inhibitor and its predictive biomarker in clear cell carcinoma of the ovary
- Principal Investigator
  
  Oishi Tetsuro
- Project Period (FY)
  2013 – 2015
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Obstetrics and gynecology
- Research Institution
  Tottori University
Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach
- Principal Investigator
  
  ITAMOCHI Hiroaki
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Obstetrics and gynecology
- Research Institution
  Tottori University

All 2018 2017 2014 2013

All Journal Article Presentation

[Journal Article] Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.2017
- Author(s)
  Chiba Y, Sato S, Itamochi H, Suga Y, Fukagawa T, Oumi N, Oishi T, Harada T, Sugai T, Sugiyama T
- Journal Title
  
  Human Cell
  
  Volume: 30 Pages: 140-148
- DOI
  10.1007/s13577-016-0154-6
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-16K11151
[Journal Article] Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.2017
- Author(s)
  Chiba Y, Sato S, Itamochi H, Yoshino N, Fukagawa D, Kawamura H, Suga Y, Kojima-Chiba A, Muraki Y, Sugai T, Sugiyama T.
- Journal Title
  
  Int J Gynecol Cancer.
  
  Volume: 8 Pages: 1666-1674
- DOI
  10.1097/igc.0000000000001081
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K11151, KAKENHI-PROJECT-17K08700
[Journal Article] The PI3K/mTOR dual Inhibitor NVP-BEZ235 Reduces Growth of Ovarian Clear Cell Carcinoma.2014
- Author(s)
  Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
- Journal Title
  
  Oncology Report
  
  Volume: 32
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-25462594
[Journal Article] Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.2014
- Author(s)
  Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, Kigawa J, Harada H.
- Journal Title
  
  Int J Gynecol Cancer
  
  Volume: 24 Pages: 61-69
- DOI
  10.1097/igc.0000000000000014
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24592517
[Journal Article] Dual inhibition of phosphatidylinositol 3’-kinase and mammalian target of rapamycin using NVP-BEZ235 as a vovel therapeutic approach for mucinous adenocarcinoma of the ovary.2014
- Author(s)
  Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
- Journal Title
  
  Int J Gynecol Cancer
  
  Volume: 24 Pages: 444-453
- DOI
  10.1097/igc.0000000000000091
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24592517
[Journal Article] Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.2013
- Author(s)
  Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M., Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N., Kigawa J., and Harada T.
- Journal Title
  
  Human Cell
  
  Volume: 26 Pages: 121-127
- DOI
  10.1007/s13577-013-0062-y
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24592517
[Presentation] Molecular and genetic alterations in ovarian clear cell carcinoma.2018
- Author(s)
  佐藤誠也, 板持広明.
- Organizer
  第60回日本婦人科腫瘍学会学術講演会
- Data Source
  KAKENHI-PROJECT-16K11151
[Presentation] Aurora-A inhibition synergistically enhances cisplatin induced cytotoxicity in ovarian clear cell carcinoma cell lines.2017
- Author(s)
  Chiba Y, Sato S, Fukagawa D, Suga Y, Kagabu M, Chiba A, Takeuchi S, Itamochi H, Sugai T, Sugiyama T.
- Organizer
  5th Biennial Meeting of Asian Society of Gynecologic Oncology
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K11151
[Presentation] 卵巣明細胞癌に対するAurora kinase A阻害剤を用いた至適併用化学療法の探索.2017
- Author(s)
  千葉洋平, 佐藤誠也, 板持広明, 杉山徹.
- Organizer
  第76回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-16K11151

1. ITAMOCHI Hiroaki (20314601)

# of Collaborated Projects: 4 results

# of Collaborated Products: 9 results
2. SATO Syinya (10423261)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
3. HARADA Tasuku (40218649)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
4. SHIMADA Muneaki (40362892)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
5. CHIKUMI Jun (70467702)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
6. OISHI Tetsuro (80359877)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
7. KIGAWA Junzo (00177784)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
8. 利部正裕 (30382609)

# of Collaborated Projects: 2 results

# of Collaborated Products: 1 results
9. 小島淳美 (60508753)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
10. 小見英夫 (20382608)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
11. 杉山徹 (40162903)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
12. 竹内聡 (60252772)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
13. 庄子忠宏 (00337148)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
14. 永沢崇幸 (10453309)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
15. 苫米地英俊 (10771363)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
16. 深川安寿子 (30772511)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
17. 馬場長 (60508240)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
18. NANIWA Jun

# of Collaborated Projects: 0 results

# of Collaborated Products: 4 results
19. 菅井有

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

SATO Seiya 佐藤 誠也

Research Projects

Research Products

Co-Researchers

卵巣明細胞癌に対するNEFHを標的とした新規治療法の開発Ongoing

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

The KANK1 pathway may be a novel therapeutic target for ovarian clear cell carcinoma

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of combination therapy using PI3K inhibitor and its predictive biomarker in clear cell carcinoma of the ovary

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.2017

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.2017

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The PI3K/mTOR dual Inhibitor NVP-BEZ235 Reduces Growth of Ovarian Clear Cell Carcinoma.2014

Author(s)

Journal Title

Data Source

[Journal Article] Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Dual inhibition of phosphatidylinositol 3’-kinase and mammalian target of rapamycin using NVP-BEZ235 as a vovel therapeutic approach for mucinous adenocarcinoma of the ovary.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.2013

Author(s)

Journal Title

DOI

Data Source

[Presentation] Molecular and genetic alterations in ovarian clear cell carcinoma.2018

Author(s)

Organizer

Data Source

[Presentation] Aurora-A inhibition synergistically enhances cisplatin induced cytotoxicity in ovarian clear cell carcinoma cell lines.2017

Author(s)

Organizer

Data Source

[Presentation] 卵巣明細胞癌に対するAurora kinase A阻害剤を用いた至適併用化学療法の探索.2017

Author(s)

Organizer

Data Source

SATO Seiya 佐藤誠也